The global cardiovascular drug market

Quirk, Jeremy; Maidwell, Nicola
April 2004
International Journal of Medical Marketing;Apr2004, Vol. 4 Issue 2, p96
Academic Journal
Presents an overview of the global cardiovascular drug market. Expectation of the growth of the value of the cardiovascular market in future; Dependence of the size and shape of the cardiovascular market on strong and often opposing forces; Definition and treatment of the cardiovascular disease in terms of individual risk factors; Dependency of a drug's success in the cardiovascular market on the ability to improve patient health.


Related Articles

  • Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization. Neil, H. Andrew W.; DeMicco, David A.; Luo, Don; Betteridge, D. John; Colhoun, Helen M.; Durrington, Paul N.; Livingstone, Shona J.; Fuller, John H.; Hitman, Graham A. // Diabetes Care;Nov2006, Vol. 29 Issue 11, p2378 

    OBJECTIVE -- Rates of cardiovascular disease are highest in the elderly. Lipid-lowering statin therapy reduces the proportional risk as effectively in older patients as in younger individuals; however, limited data are available for elderly patients with type 2 diabetes. We conducted a post hoc...

  • Ticagrelor was more effective than clopidogrel in acute coronary syndromes with planned invasive treatment. Brophy, James M. // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p3 

    The article reports on a study that discusses safety and efficiency of ticagrelor and clopidogrel in patients with planned invasive management of an acute coronary syndrome (ACS). As stated, based on a secondary analysis of randomized controlled trial, thousands of patients were admitted for an...

  • Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Schaefer, Juergen R.; Gitt, Anselm K.; Sonntag, Frank; Weizel, Achim; Jannowitz, Christina; Karmann, Barbara; Pittrow, David; Bestehorn, Kurt // Vascular Health & Risk Management;2013, Vol. 9, p71 

    Aims: We aimed to document the drug management of patients at high cardiovascular risk in daily practice, with the special focus on lipid-lowering treatment. Methods and results: In this prospective noninterventional study in 2387 outpatient centers throughout Germany, a total of 13,942...

  • Efficacy of Statin Treatment in Early-Stage Chronic Kidney Disease. Cho, Eun Yeong; Myoung, Chana; Park, Hong-suk; Kim, Ae Jin; Ro, Han; Chang, Jae Hyun; Lee, Hyun Hee; Chung, Wookyung; Jung, Ji Yong // PLoS ONE;1/12/2017, Vol. 12 Issue 1, p1 

    Chronic kidney disease (CKD) represents a major medical challenge and frequently coexists with cardiovascular disease (CVD), which can be treated by statin trerapy. However, whether statin treatment affects renal progression and outcomes in CKD patients remains unclear. We retrospectively...

  • Nateglinide does not reduce CV events in patients with impaired glucose tolerance.  // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p54 

    The article reports on a study which found that nateglinide does not prevent cardiovascular (CV) events in patients with impaired glucose tolerance.

  • Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. Gagne, Joshua J.; Choudhry, Niteesh K.; Kesselheim, Aaron S.; Polinski, Jennifer M.; Hutchins, David; Matlin, Olga S.; Brennan, Troyen A.; Avorn, Jerry; Shrank, William H. // Annals of Internal Medicine;9/16/2014, Vol. 161 Issue 6, p400 

    Background: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. Objective: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence...

  • The appropriate clinical use of niacin in the treatment of dyslipidemia. Houston, Mark; Guarneri, Mimi; Kahn, Joel // Clinical Lipidology;Feb2015, Vol. 10 Issue 1, p17 

    The authors discuss the results of a study which examined the use of niacin to treat dyslipidemia and cardiovascular disease (CVD). They emphasize the effectiveness of niacin for treating defined types of dyslipidemia and reducing CVD in addition to having a low incidence of adverse effects....

  • Sex differences in the effectiveness of statins after myocardial infarction. Karp, Igor; Chen, Shun-Fu; Pilote, Louise // CMAJ: Canadian Medical Association Journal;1/30/2007, Vol. 176 Issue 3, p333 

    Background: We sought to investigate the sex differences in the effectiveness of statins in patients with acute myocardial infarction (AMI). Methods: Linking hospital discharge and drug claims databases from Quebec, Canada (1998–2004), we identified statin users (n = 14 710) and non-users...

  • Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes. SATHYAPALAN, THOZHUKAT; ATKIN, STEPHEN L.; KILPATRICK, ERIC S. // Diabetes Care;Sep2010, Vol. 33 Issue 9, p1948 

    OBJECTIVE- Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic...

  • Adverse cardiovascular response to oral trimeprazine in children. Loan, W.H.; Cuthbert, D. // British Medical Journal (Clinical Research Edition);5/25/1985, Vol. 290 Issue 6481, p1548 

    Examines the adverse cardiovascular response to oral trimeprazine in children. Utilization of trimeprazine as premedicant and general pediatric sedative; Absence of hypotensive complications; Factors arising from preanesthetic sedatives.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics